Impact of Omalizumab on Anaphylaxis in Patients Treated for Chronic Urticaria.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: S. Karger Country of Publication: Switzerland NLM ID: 9211652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0097 (Electronic) Linking ISSN: 10182438 NLM ISO Abbreviation: Int Arch Allergy Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel ; New York : S. Karger, 1992-
    • Subject Terms:
      Anaphylaxis*/prevention & control ; Chronic Urticaria*/drug therapy ; Urticaria*/drug therapy ; Anti-Allergic Agents*; Adult ; Humans ; Omalizumab/adverse effects ; Histamine H1 Antagonists ; Chronic Disease ; Treatment Outcome
    • Abstract:
      Background: Anaphylaxis is a life-threatening systemic allergic reaction. Omalizumab (OMA) is an established treatment in chronic urticaria (CU), but experience in anaphylaxis is limited.
      Objectives: The objective was to evaluate the efficacy and safety of OMA on anaphylaxis in patients with CU who are resistant to antihistamine therapy and have a history of anaphylaxis.
      Method: Patients with antihistamine-resistant CU and a history of anaphylaxis were eligible. OMA was given 300 mg/150 mg every 4 weeks. Urticaria control test (UCT) scores, the episodes of anaphylaxis, and adverse events were recorded during the OMA treatment.
      Results: A total of 7 adults were included. After starting OMA, all of them achieved a complete control (UCT = 16) after 3 months of OMA treatment; 6 of them did not suffer any attack of anaphylaxis in the follow-up periods (5 patients for more than 12 months and 1 patient for 4 months). No adverse events were observed.
      Conclusion: The study indicated the efficacy and safety of OMA for antihistamine-resistant CU patients with a history of anaphylaxis and its potential as a prevention option for anaphylaxis.
      (© 2022 The Author(s). Published by S. Karger AG, Basel.)
    • References:
      J Allergy Clin Immunol. 2014 May;133(5):1365-72, 1372.e1-6. (PMID: 24522090)
      J Allergy Clin Immunol. 2021 Mar;147(3):1004-1010.e2. (PMID: 33220353)
      Allergy. 2009 Sep;64(9):1256-68. (PMID: 19650847)
      J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e743-e745. (PMID: 34310766)
      Ann Allergy Asthma Immunol. 2021 Oct;127(4):481-487. (PMID: 34175498)
      J Allergy Clin Immunol. 2014 Feb;133(2):461-7. (PMID: 24144575)
      Allergy. 2017 Apr;72(4):519-533. (PMID: 27861988)
      J Allergy Clin Immunol. 2006 Feb;117(2):391-7. (PMID: 16461139)
      Ann Allergy Asthma Immunol. 2016 Aug;117(2):115-20. (PMID: 27499538)
    • Contributed Indexing:
      Keywords: Anaphylaxis; Chronic urticaria; Omalizumab
    • Accession Number:
      2P471X1Z11 (Omalizumab)
      0 (Histamine H1 Antagonists)
      0 (Anti-Allergic Agents)
    • Publication Date:
      Date Created: 20221103 Date Completed: 20230207 Latest Revision: 20230907
    • Publication Date:
      20231215
    • Accession Number:
      PMC9932819
    • Accession Number:
      10.1159/000527158
    • Accession Number:
      36327946